PING Act
The source supplies the latest action, but no lifecycle stage.
Latest action (14 Apr 2021): Read twice and referred to the Committee on Finance.
What this bill does
The PING Act, introduced in the Senate, aims to prevent changes to the Medicare prescription drug benefit program, known as Medicare Part D. Specifically, it expresses the Senate's opinion that current rules preventing the Centers for Medicare & Medicaid Services (CMS) from negotiating drug prices or creating a formulary for these drugs should remain in place. The bill would also prohibit CMS from testing any new healthcare models that would remove or waive these existing restrictions.
This legislation affects Medicare beneficiaries by aiming to maintain the current structure of prescription drug coverage, which the bill's findings suggest offers a wide choice of medications and plans. It also impacts CMS by limiting its ability to test certain pricing or formulary models for prescription drugs within the Medicare Part D program. The bill's findings highlight the importance of a broad range of treatment options for individuals with chronic conditions.
As of its introduction on April 14, 2021, the PING Act has been referred to the Senate Committee on Finance. There have been no further actions on the bill since its introduction. If the bill were to advance, it would require further committee review and potentially a vote by the full Senate, followed by passage in the House of Representatives and the President's signature to become law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Preserving Innovation for the Next Generation Act or the PING Act
This bill expresses the sense of the Senate that the current restrictions prohibiting the Centers for Medicare & Medicaid Services from negotiating the prices or establishing a formulary for drugs under the Medicare prescription drug benefit should not be repealed. The bill also prohibits the Center for Medicare and Medicaid Innovation from testing any model that would repeal or require a waiver of such restrictions.
Timeline
14 Apr 2021
Read twice and referred to the Committee on Finance.
Common questions
- What does S. 1123 do?
- The PING Act, introduced in the Senate, aims to prevent changes to the Medicare prescription drug benefit program, known as Medicare Part D. Specifically, it expresses the Senate's opinion that current rules preventing the Centers for Medicare & Medicaid Services (CMS) from negotiating drug prices or creating a formulary for these drugs should remain in place. The bill would also prohibit CMS from testing any new healthcare models that would remove or waive these existing restrictions. This legislation affects Medicare beneficiaries by aiming to maintain the current structure of prescription drug coverage, which the bill's findings suggest offers a wide choice of medications and plans. It also impacts CMS by limiting its ability to test certain pricing or formulary models for prescription drugs within the Medicare Part D program. The bill's findings highlight the importance of a broad range of treatment options for individuals with chronic conditions. As of its introduction on April 14, 2021, the PING Act has been referred to the Senate Committee on Finance. There have been no further actions on the bill since its introduction. If the bill were to advance, it would require further committee review and potentially a vote by the full Senate, followed by passage in the House of Representatives and the President's signature to become law.
- Has S. 1123 become law?
- The source does not supply a confirmed lifecycle stage for S. 1123. Check the latest action and official source below.
- Who sponsored S. 1123?
- S. 1123 was sponsored by Sen. Blackburn, Marsha [R-TN] (R-TN), with 1 cosponsor.
- What's the latest action on S. 1123?
- Read twice and referred to the Committee on Finance. (14 Apr 2021).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
340B Rebate Model Delay Act
Lower Premiums, Faster Payments Act
More bills from Sen. Blackburn, Marsha [R-TN]
Biosimilars Access and Affordability Act
Title IX Clarification Act of 2026
A resolution condemning the Government of the Islamic Republic of Iran for its ongoing human rights abuses, including its use of politically motivated espionage claims to justify arbitrary detention and executions.
Daughters of the American Revolution Membership Integrity Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.